Login / Signup

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.

Domenica LorussoFrancesco RaspagliesiDominique RonzulliGiorgio ValabregaNicoletta ColomboCarmela PisanoChiara CassaniGermana TognonStefano TamberiGiorgia MangiliSerafina MammolitiUgo De GiorgiFilippo GrecoAnna Maria MosconiEnrico BredaGrazia ArtioliClaudia AndreettaClaudia CasanovaRita CeccheriniAntonio FrassoldatiVanda SalutariSerena GiolittoGiovanni Scambia
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Trabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy.
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • primary care
  • emergency department
  • phase ii
  • locally advanced
  • double blind
  • placebo controlled
  • study protocol
  • rectal cancer
  • squamous cell carcinoma
  • chemotherapy induced